A major study led by researchers at the Nuffield Department of Primary Care Health Sciences, University of Oxford has found that blood pressure-lowering medication is more likely to prevent serious cardiovascular events, such as heart attacks and strokes, than cause serious falls, even among older people and those living with frailty.
The research, funded by the Wellcome Trust and the National Institute for Health and Care Research (NIHR), analysed anonymised health records from more than 5.5 million patients in England and provides new evidence to help doctors weigh up the benefits and potential harms of treatment for individual patients.
High blood pressure is a leading cause of heart disease and stroke worldwide. Although medication can substantially reduce these risks, doctors must also consider potential side effects, including dizziness, fainting, falls and kidney problems. These concerns are particularly important for older patients with frailty, who may be more vulnerable to adverse effects.
Balancing the benefits and risks of blood pressure treatment
To investigate how the benefits and risks of blood pressure treatment differ between patients, researchers developed a new cardiovascular risk calculator, called STRATIFY-CVD, using routinely collected NHS patient records. The tool estimates a person's likelihood of experiencing a serious cardiovascular event, such as a heart attack or stroke, in the next five to ten years based on factors including their age, medical history and existing health conditions.
The researchers then combined these predictions with existing models that estimate the risk of medication-related side effects, alongside evidence from clinical trials examining the effects of blood pressure-lowering drugs. This allowed them to estimate how many heart attacks and strokes blood pressure treatment could prevent, compared with the number of adverse events it might cause, over a ten-year period.
The researchers estimated that, for every 1,000 patients treated over ten years, blood pressure-lowering medication would prevent approximately eight serious cardiovascular events, such as heart attacks and strokes, while causing around two serious falls.
The findings also suggest that the benefits of treatment outweigh the risk of serious falls among older patients living with frailty, even though these patients are more vulnerable to medication-related falls.
For example, the researchers estimated that treating 1,000 men in their 80s with moderate frailty over ten years would prevent 47 serious cardiovascular events, compared with nine serious falls caused by medication. By comparison, treating 1,000 fit men in their 60s with no history of cardiovascular disease was estimated to prevent 12 serious cardiovascular events while causing one serious fall.
However, the findings revealed a more complex picture for other potential side effects. For fainting and acute kidney injury, the benefits and harms of treatment were more finely balanced. For low blood pressure and elevated potassium levels (which can lead to heart palpitations and shortness of breath), the models suggested that treatment could cause more adverse events than cardiovascular events prevented, although these side effects are generally less serious than a heart attack or stroke.
Professor James Sheppard, from the Nuffield Department of Primary Care Health Sciences, University of Oxford and senior author on the paper, said:
"Deciding whether to prescribe blood pressure medication isn't always straightforward, particularly when someone is older, living with frailty or several other health conditions. Doctors need to consider not just whether a treatment works, but how much an individual patient is likely to benefit and what risks matter most to them.
"Until now, it has been difficult to bring all this information together in a simple way that informs these treatment decisions. Our research is an important step towards giving doctors and patients a clearer, more personalised picture of what treatment might mean for them.
"Ultimately, we want to help people make informed choices about their treatment, based on the best available evidence and what matters most to them."
Towards more personalised treatment options
Existing cardiovascular risk calculators are not always suitable for people who have previously experienced a heart attack or stroke, those already taking cholesterol-lowering medication, or the very oldest patients.
STRATIFY-CVD was developed to address these limitations, taking account of a person's medical history, existing health conditions and medication use. It also considers the possibility of someone dying from another cause before experiencing a heart attack or stroke.
The researchers found that the model accurately predicted cardiovascular risk when tested against an independent dataset of patient records. It generally produced lower risk estimates than the previously widely used QRISK2 calculator, suggesting that some existing approaches may overestimate cardiovascular risk. More information about the calculator, including how it can be downloaded for use in further research, can be found here .
The team also developed a chart illustrating how the estimated benefits and harms of treatment vary across different patient groups, including by age, sex, frailty and previous cardiovascular disease. This could help doctors and patients discuss treatment options and make more informed decisions.
The researchers explain that by showing that the cardiovascular benefits of blood pressure medication can outweigh the risk of serious falls, even in older patients living with frailty, the findings could help inform future treatment guidelines and support more confident, personalised prescribing decisions.